Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
CEO: Garo H. Armen. Company website
Protagenic Therapeutics, Inc. (PTIX) trades at $0.26, up 30.00% on the day, as of Sep 20, 2026 14:59 UTC.
Protagenic Therapeutics, Inc. has a market capitalisation of $503,068.02, calculated from the live PTIX share price and shares outstanding.
PTIX has no meaningful price-to-earnings ratio: Protagenic Therapeutics, Inc. lost $3.45 per share over the last twelve months, and a P/E is only defined on positive earnings.
Protagenic Therapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.
PTIX has traded between $0.17 and $1.20 over the past 52 weeks, and the last price is 78.3% below that high.
Yes. Protagenic Therapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
Wall Street analysts rate PTIX Buy.
Protagenic Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Garo H. Armen is the chief executive of Protagenic Therapeutics, Inc., which employs 1 people.
QFI Terminal shows PTIX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PTIX in Terminal See plans